Original ContributionKillip classification in patients with acute coronary syndrome: insight from a multicenter registry☆
Introduction
Killip classification is a simple clinical tool that has been previously studied in patients with ST-elevation myocardial infarction (STEMI) [1], [2], [3]. According to Killip and Kimball criteria, patients were classified into 4 classes during physical examination. Patients in Class I demonstrated no evidence of heart failure (HF). Patients in Class II had findings consistent with mild to moderate HF; patients in Class III demonstrated overt pulmonary edema and patients in Class IV were in cardiogenic shock [2]. Post-MI risk stratification that has been derived from several clinical trials is important to set the appropriate treatment and prognosis. Patients with higher Killip class were found to have more severe angiographic coronary artery disease, higher incidence of ventricular dysfunction, and larger myocardial infarctions [2], [3]. However, similar data from patients with non–ST-elevation acute coronary syndrome (NSTEACS) are limited. Awareness of patients' Killip class at the presentation is a crucial step in the risk stratification strategy. Herein, we assess the incidence and prognostic value of Killip classification at the presentation in different types of the ACS spectrum.
Section snippets
Methods
Data are derived from a prospective, observational, multinational, multicenter study of the Gulf Registry of Acute Coronary Events (Gulf RACE). In 2007 and for 5 months, Gulf RACE recruited 6704 consecutive ACS patients from 64 hospitals in 6 Middle Eastern countries (Bahrain, Kuwait, Qatar, Oman, United Arab Emirates, and Yemen). The study received ethical approval from the institutional ethical bodies in all participating countries. The rationale and details of Gulf RACE have been described
Results
Killip classes (I, II, III, and IV) were successfully defined in 6689 patients. Patients with high Killip class (II = 13%, III = 7%, and IV = 2%) were older and had a greater prevalence of previous coronary artery disease, diabetes, hypertension, dyslipidemia, and renal impairment in comparison to Killip Class I. Table 1, Table 2 summaries baseline characteristics of patients presenting with ACS in different Killip classes. Patients with STEMI and NSTEACS had almost similar baseline
Discussion
The current study evaluated the incidence and prognosis of the on-admission Killip classification in patients presenting with ACS. The key findings of this study were the following: (1) Killip Class II, III, and IV patients had higher risk profiles and rates of major adverse clinical events across ACS. (2) Despite their higher inherent risk, patients with higher Killip class continued to receive less coronary angiography and less evidence-based therapies compared with their counterparts in
References (16)
- et al.
Association of Killip class on admission and left ventricular dilatation after myocardial infarction: a closer look into an old clinical classification
Am Heart J
(1999) - et al.
Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction
Am J Cardiol
(2001) - et al.
Comparison of men and women with acute coronary syndrome in six Middle Eastern countries
Am J Cardiol
(2009) - et al.
Patterns of use and potential impact of early beta-blocker therapy in non–ST-elevation myocardial infarction with and without heart failure: the Global Registry of Acute Coronary Events
Am Heart J
(2006) - et al.
Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction
Am J Cardiol
(1988) - et al.
Prognostic importance of physical examination for heart failure in non–ST-elevation acute coronary syndromes: the enduring value of Killip classification
JAMA
(2003) - et al.
Management and outcomes of Middle Eastern patients admitted with acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE)
Acta Cardiol
(2009) - et al.
Gulf RACE investigators. Heart failure in patients hospitalized with acute coronary syndromes: observations from the Gulf Registry of Acute Coronary Events (Gulf RACE)
Eur J Heart Fail
(2009)
Cited by (66)
The association between Day-1 urine cadmium excretion and 30-day mortality in patients with acute myocardial infarction: A multi-institutional cohort study
2023, International Journal of CardiologyCitation Excerpt :Although the development of percutaneous coronary interventions and thrombolytic drugs have decreased the mortality rate of acute myocardial infarction (AMI), the detection of high-risk patient is a challenge. Several prognostic scoring systems for use in a critical care setting have been developed for use in patients with AMI, including Acute Physiology and Chronic Health Evaluation (APACHE II) [2], Sequential Organ Failure Assessment (SOFA) [3], and Killip scores [4]. However, these scoring systems are complicated and significant differences exist in inter-observer variability with regards to diagnostic classification.
Association between inflammation and left ventricular thrombus formation following ST-elevation myocardial infarction
2022, International Journal of CardiologyEchocardiographic Killip Classification
2022, Journal of the American Society of EchocardiographyC-reactive protein velocity predicts microvascular pathology after acute ST-elevation myocardial infarction
2021, International Journal of CardiologyCitation Excerpt :Only stable STEMI patients with Killip class <3 and a delay <12 h were included in this analysis. Notably, the vast majority of STEMI patients present with Killip class <3 [39]. The predictive value of CRPv on MVO might thus not be applicable to unstable patients or NSTEMI.
Higher 1-year mortality on rest days in patients with acute coronary syndromes and decompensated heart failure—A SPUM-ACS sub-study
2024, Catheterization and Cardiovascular Interventions
- ☆
Funding: Gulf Registry of Acute Coronary Events (Gulf RACE) is a Gulf Heart Association project and was financially supported by Sanofi Aventis, Paris, and Qatar Telecommunications Company, Doha, Qatar. The sponsors had no role in study design, data collection, data analysis, writing of the report or submission of the manuscript.